Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jan 07 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced a new agreement with CVS Caremark to include its products Zituvio, Zituvimet, and Zituvimet XR in CVS's template formulary. This partnership aims to enhance patient access to these diabetes medications, which have been approved by the USFDA. The press release emphasizes Zydus's commitment to improving healthcare access and its strategic investments in innovative products.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 07, 2025, titled "Zydus announces agreement with CVS Caremark to add Zituvio TM, Zituvimet TM and Zituvimet TM XR (Sitagliptin Sitagliptin and Metformin Hydrochloride) to its template formulary".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases